SONNET BIOTHERAPEUTICS HOLDI (SONN)
US83548R3030 - Common Stock
SONNET BIOTHERAPEUTICS HOLDI
NASDAQ:SONN (11/4/2024, 8:00:02 PM)
4.33
+0.01 (+0.23%)
Company Profile
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 12 full-time employees. The company went IPO on 2005-07-27. The firm's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The firm designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.
Company Info
SONNET BIOTHERAPEUTICS HOLDI
100 Overlook Center, Suite 102
Princeton NEW JERSEY 08540
P: 16093752227
CEO: Pankaj Mohan
Employees: 12
Website: https://www.sonnetbio.com/
SONN News
19 days ago - Sonnet BioTherapeutics Holdings, Inc.Sonnet BioTherapeutics Inc. Regains Compliance with NasdaqPRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage...
a month ago - Sonnet BioTherapeutics Holdings, Inc.Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in IndiaSonnet to receive $1.0 million in upfront payment and up to an additional$1.0 million in milestone payments with a royalty in the low double digits on net...
a month ago - Sonnet BioTherapeutics Holdings, Inc.Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive ProgramsPRINCETON, NJ, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage...
a month ago - Sonnet BioTherapeutics Holdings, Inc.Sonnet BioTherapeutics Announces Launch of CEO Corner PlatformCEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Provides interested...
a month ago - Sonnet BioTherapeutics Holdings, Inc.Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock SplitPRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical...
2 months ago - Sonnet BioTherapeutics Holdings, Inc.Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid TumorsSON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 Phase 1 study expected by Q4...
SONN Twits
Here you can normally see the latest stock twits on SONN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
